Erolin

Quick links to important sections

Erolin

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Erolin

Property Description
Active Ingredient Loratadine (INN)
Form Tablet, Oral Solution, Syrup
Pharmacological Class Second-generation Antihistamine
General Purpose Relieving allergic symptoms
Origin Synthetic

What is Erolin and its Core Composition?

Erolin is a synthetic pharmaceutical preparation intended for oral intake, whose sole active component is the substance Loratadine (INN), classified chemically as a piperidine derivative. It is a single-component product typically supplied in common oral dosage forms, including the solid tablet and the liquid syrup or oral solution. This composition means Erolin contains only Loratadine along with essential inactive components, focusing its entire action on the core therapeutic purpose. Loratadine possesses a high affinity for peripheral histamine receptors.


Erolin's Place in Antihistamine Therapy

Erolin is classified pharmacologically as a second-generation antihistamine, functioning specifically as a highly selective peripheral H1-receptor blocker. This placement within the antiallergic agent class is crucial because the drug is engineered to target receptors primarily outside the central nervous system. This design prevents substantial penetration across the blood-brain barrier, resulting in the drug's classification as a non-sedating antihistamine, a characteristic that differentiates it from older first-generation agents. This class of drugs is designed to provide allergy relief with minimal sedative side effects.


General Benefit: Relieving Allergic Symptoms

The general purpose of Erolin is to provide systemic relief from the discomforts associated with the body's overreaction to allergens, satisfying the need for an effective antiallergic agent. It achieves this by the fundamental principle of selective histamine H1 receptor inhibition, which blocks the natural chemical messenger, histamine, from causing typical allergic symptoms like irritation and inflammation. As an antihistamine, Loratadine provides symptomatic control for allergic rhinitis. This action provides general symptomatic relief, such as the temporary easing of discomfort associated with seasonal allergy symptoms.

Regulatory References

  1. National Institutes of Health (NIH) Drug Information
  2. NIH Loratadine Facts

What side effects are possible with Erolin?

Possible Side Effects and Safety Information

Official regulatory documents classify the possible adverse reactions associated with Erolin (loratadine) according to frequency and physiological system.


Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions, classified as Common in regulatory labeling (potentially affecting up to 1 in 10 people), include headache, somnolence (drowsiness), and insomnia. Adverse reactions reported as Very Rare (potentially affecting up to 1 in 10,000 people) are numerous and span several organ systems.


System-Organ Classification and Serious Events

Side effects are grouped by the System-Organ Class (SOC) they affect. Examples of SOCs listed in official safety profiles include Nervous system disorders, Gastrointestinal disorders (e.g., dry mouth, nausea), Skin and subcutaneous tissue disorders (e.g., rash, alopecia), and Cardiac disorders.

Serious Adverse Reactions officially documented as Very Rare include anaphylaxis (a severe allergic reaction), convulsions, tachycardia (rapid heart rate), and hepatic function abnormal (disturbances in liver function). The inclusion of these events in the official labeling defines the upper tier of potential risk.


Population-Specific Safety Notes

The official prescribing information includes specific safety considerations for certain patient populations. Caution is advised for individuals with severe hepatic impairment, as their condition may affect the drug’s metabolism. Additionally, regulatory guidance notes are applicable regarding the use of the medicine in the pediatric population and during pregnancy or lactation.

Overdose and Emergency Response

Overdose Manifestations and Emergency Action

The official regulatory profile for Erolin (Loratadine) overdose is centered on specific clinical manifestations and mandated emergency actions. Following the ingestion of doses substantially higher than the recommended amount, the most frequently documented signs include somnolence (drowsiness), a rapid heart rate (tachycardia), and headache. In cases of massive ingestion, regulatory sources have reported more severe presentations, such as palpitations and extrapyramidal signs.

When to Seek Immediate Medical Help

Any time an Erolin overdose is suspected, it is officially mandated to seek immediate medical attention. This action involves contacting emergency services or a poison control center immediately, as stipulated by regulatory guidance. Specific overdose notes in pediatric populations (ages 1 to 2) indicate a higher incidence of somnolence and tachycardia following exposure to doses greater than 10 mg.

Official Management and Monitoring

Management of a Loratadine overdose is officially described as symptomatic and supportive. The regulatory information clarifies that no specific antidote is known for reversing the drug's effects. To limit systemic absorption, procedures such as gastric lavage or the administration of activated charcoal may be considered. Due to the potential for high-dose cardiovascular effects, specialized procedures, including Electrocardiogram (ECG) monitoring, may be required to safely observe the patient's condition.

Therapeutic Uses of Erolin

Main Uses and Benefits of Erolin

Quick Facts: Uses of Erolin

  • Aids in managing symptoms associated with seasonal and year-round allergies.
  • Contributes to the relief of signs related to allergic rhinitis (hay fever).
  • May provide relief from conditions such as chronic urticaria (hives) and other allergic skin disorders.

Erolin is used for managing symptoms related to certain allergic conditions. Its main therapeutic application is to provide temporary relief from the signs associated with hay fever and other upper respiratory tract allergies. These indications commonly include reducing runny nose, sneezing, and the itching and watering of the eyes, nose, or throat.

Additionally, Erolin is used to address symptoms of chronic idiopathic urticaria, which is characterized by itchy skin rashes (hives). It may assist in reducing the visible signs and accompanying discomfort of allergic skin conditions. Patients should consult a healthcare professional for a complete therapeutic overview of Erolin and its approved uses.

The overall goal of the treatment is to offer symptom control within the established duration of use.

Eligibility and Restrictions for Use

Who can and cannot use Erolin?

The eligibility for Erolin (loratadine) is formally established by regulatory bodies like the FDA and EMA and is based primarily on age and specific pre-existing health conditions.

Erolin is generally approved for adults and adolescents 12 years of age and older, and for children 6 years of age and older. Use is not recommended for children younger than 6 years, as safety and efficacy data are not established for this group.


Official Eligibility Restrictions

Status Population or Condition
Absolute Contraindication Patients with known hypersensitivity to loratadine or its metabolite, desloratadine.
Conditional Use (Restricted) Patients with severe hepatic impairment (liver disease) or severe renal impairment (kidney disease). Use requires a lower starting dose as mandated by regulatory labeling.
Conditional Use (Physiological) Pregnant women (use permitted only if benefit justifies risk, e.g., FDA Category B) and breastfeeding women (use generally not recommended due to drug excretion into breast milk).

These official statements define who is eligible for standard use and who requires exclusion or special dosing consideration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Erolin (Loratadine) is primarily defined by pharmacokinetic interactions resulting from altered drug metabolism, as documented in regulatory prescribing information. Co-administration with specific medications can lead to an increase in the systemic concentration of Loratadine and its active metabolite, Desloratadine.

Documented Pharmacokinetic Interactions

Interacting Medicine Interaction Outcome (Regulatory Description)
Ketoconazole Leads to a significant increase in plasma concentrations of Loratadine and Desloratadine.
Erythromycin Causes an increase in the area under the curve (AUC) and peak plasma concentration (Cmax) of Loratadine.
Cimetidine Results in increased systemic exposure (AUC and Cmax) of Loratadine.

These interactions are consistent with the inhibition of metabolic pathways responsible for Loratadine clearance. The regulatory documentation does not specify mandatory timing separation rules for these combinations, nor does it list any drug combinations as formally contraindicated.

Interactions with Food and Alcohol

Official regulatory studies have addressed interactions with common substances. Co-administering Loratadine with food is documented to delay the time to reach peak plasma concentration (Tmax), but it does not change the overall extent of absorption. Additionally, official reports confirm that Loratadine does not potentiate the effects of alcohol (no increase in psychomotor impairment).

Population-Specific Notes

The risk of these exposure-altering pharmacokinetic interactions may be more relevant in individuals diagnosed with severe hepatic impairment, as noted in official regulatory labeling.

Mechanism of Action

Modulating Receptor-Mediated Signaling

Erolin acts primarily on specific cell-surface receptors within targeted tissues. The drug functions as an antagonist, binding to the receptor site and initiating or suppressing signaling sequences that modify early molecular steps. This mechanism results in the modulation of signal transduction that influences localized cellular and physiological activity driven by distinct signaling patterns.


Regulating Key Signaling Cascades

By engaging these receptors, Erolin modifies pathway activity that is typically governed by specific neurotransmitters or mediators. This molecular interaction alters the resultant intracellular signal level generated by these mediators. Through this process, the drug promotes the establishment of altered equilibrium within targeted pathways, thereby restricting the cascade of subsequent molecular events.


Influencing Dysregulated Processes

This mechanism of action encompasses the drug’s ability to influence systems where overactive or dysregulated processes dominate. The specific biochemical actions—receptor antagonism and subsequent pathway modification—lead to downstream physiological alterations that define the pharmacological response at the system level.

Dosage and Administration Information

How to Use Erolin

Erolin (Loratadine) is administered via the oral route using available dosage forms, which include the tablet and oral solution or syrup. Its use is structured by a simple, fixed daily regimen.


Official Administration Guidelines

Instruction Detail
Route of Administration Oral
Standard Frequency Once daily (q.d.).
Timing in Relation to Meals May be taken with or without food.
Missed Dose Rule If a dose is missed, take it as soon as remembered, unless it is nearly time for the next scheduled dose; in that case, skip the missed dose. Do not double dose.
Duration Pattern Used for symptom control over the required period, including both short-term seasonal use and long-term management of chronic conditions.

Labeled Dosing Regimens

Population Standard Dosing (Maximum Daily Dose: 10 mg)
Adults and Adolescents (ge 12 years) 10 mg
Children (2 to 12 years) le 30 kg 5 mg
Children (2 to 12 years) > 30 kg 10 mg

Population-Specific Dosing Adjustments

Dose adjustments are specified for individuals with organ impairment, as this affects the drug’s processing and elimination from the body. For patients with severe hepatic impairment or severe renal impairment (Clcr le 30 mL/min), the standard 10 mg dose should be administered every other day. This modification extends the time between doses to prevent the accumulation of the medicine in the system. The regimen is uniform regardless of whether the use is for short-term or chronic control.

Recent Clinical Evidence

Research Evidence Overview of Studies for Erolin

Evidence for Use in Allergic Rhinitis (Hay Fever)

The research into Erolin’s profile for allergic rhinitis is primarily based on short-term Randomized Controlled Trials (RCTs) against an inactive placebo. These studies focus on measuring changes in Total Symptom Scores (TSS), which combine measurements of multiple upper respiratory symptoms like sneezing, runny nose, and itching. Research highlights the measured changes in these scores over observation periods typically lasting between one and four weeks, providing insight into short-term symptom patterns.


Evidence for Use in Chronic Urticaria (Hives)

Erolin was evaluated in controlled trials for Chronic Urticaria, which involves persistent, itchy skin rashes. These studies monitored outcomes related to physical discomfort, such as the size and number of hives (wheals), as well as the severity of itching (pruritus). Follow-up usually lasted up to two or three months, and studies describe the patterns observed in these skin symptom changes during this intermediate-term period.


Durability and Duration of Study Follow-up

The majority of pivotal studies for Erolin were designed for short-term or episodic symptom patterns. Research indicates that follow-up durations were limited, resulting in limited information for long-term outcomes and continuous stability of response. The existing trial results apply only to the populations and specific time intervals observed.


Evidence in Different Patient Groups

While adult and adolescent populations (age 12 and older) were the primary groups studied, research was also conducted on children across different pediatric age groups, particularly when assessing the liquid or syrup formulations. However, the results apply only to the populations studied, and data for certain groups, such as those with specific concurrent medical conditions (comorbidities) or pregnant individuals, remain insufficient.


Research Gaps and Areas of Uncertainty

Studies help show what has been observed so far, but key limitations remain in several areas. There is limited information for long-term outcomes beyond the initial trial durations. Comparative evidence is lacking for specific direct comparisons against other antihistamines, particularly when assessing different or higher dosage strategies. Finally, data for certain complex patient subgroups are still emerging.

Key Studies & References Loratadine: MedlinePlus Drug Information (NIH)

Frequently Asked Questions (FAQ)

Common questions about Erolin (FAQ)

Q: What is Erolin used for besides allergies?

A: According to official regulatory documents, Erolin (Loratadine) is indicated for two main purposes: the temporary relief of symptoms associated with allergic rhinitis (commonly known as hay fever) and for treating the uncomplicated skin symptoms of chronic urticaria (long-lasting hives).

Q: How quickly does Erolin start working?

A: Studies on the drug’s absorption indicate that Erolin is rapidly taken up by the body after administration. Its effects are generally observed starting within the first one to two hours following administration, based on pharmacokinetic data.

Q: How long do the effects of Erolin last?

A: Erolin is classified as a long-acting second-generation antihistamine. Official dosing instructions call for it to be taken once daily, which is consistent with the long duration of action of the drug and its active metabolite, Desloratadine.

Q: Is it safe to drink coffee while taking Erolin?

A: Official product information does not list a specific interaction warning for Erolin (Loratadine) alone with caffeine. However, if taking Erolin in a combination product that includes a decongestant, excessive caffeine intake could potentially worsen side effects like nervousness. For comprehensive guidance on your specific medications, it is recommended to review your complete drug interaction profile with a health professional.

Q: Can Erolin be taken with heartburn medication?

A: Official information documents an interaction with Cimetidine, which is a type of medication sometimes used for heartburn and ulcers. Taking Erolin with Cimetidine can increase the concentration of Erolin in the blood. For comprehensive guidance on your specific medications, it is recommended to review your complete drug interaction profile with a health professional.

Q: How should Erolin be stored?

A: Erolin should be stored at room temperature, typically between 20 C to 25 C (68 F to 77 F). It is essential to keep the medication protected from excessive moisture and certain liquid forms should be kept out of direct light to maintain the product’s quality.

Q: Can people with kidney problems take Erolin?

A: Yes, but patients with severe renal impairment (severe kidney disease) require specific caution. Official regulatory labeling indicates that these patients may require a reduced starting regimen, such such as the standard dose administered every other day, to prevent drug accumulation.

Q: Is Erolin safe during pregnancy (general question about ingredient safety)?

A: Erolin is classified as Pregnancy Category B in official labeling. This means that while animal studies have not shown harm, there is limited data from controlled studies in pregnant women. Official guidance states that its use during pregnancy is only recommended if the expected benefit is considered to outweigh the potential risk.

Q: Is Erolin safe for long-term use?

A: The drug’s labeling indicates that Erolin may be used for the long-term management of chronic conditions such as persistent hives. However, available regulatory data primarily stems from short- to intermediate-term follow-up studies, which limits information on continuous, long-term use.

Q: Can Erolin cause stomach upset?

A: Official reports on side effects include adverse reactions that affect the gastrointestinal system. Some reported effects include nausea, gastritis (stomach irritation), and dry mouth.

Q: Does Erolin affect blood pressure?

A: Although it is considered a very rare occurrence, official regulatory documents have reported both hypotension (low blood pressure) and hypertension (high blood pressure) as potential adverse reactions associated with Loratadine.

Q: Is it normal to feel a little dizzy after taking Erolin?

A: Feeling dizzy is listed in the official safety profile as a very rare adverse reaction. It is not considered a common side effect of Erolin.

Q: Are there any long-term effects of taking Erolin regularly?

A: Official documentation lists adverse events observed in trials and post-marketing surveillance. No unique set of specific long-term effects is explicitly defined in official documentation beyond the potential for known side effects to occur during continuous use.

Q: What happens if I accidentally miss a dose of Erolin?

A: Official instructions state that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the missed dose should be skipped. It is advised in the product label not to take a double dose to compensate for a missed dose.

Q: Are there specific foods to avoid when taking Erolin?

A: No specific foods are listed as needing to be avoided when taking Erolin. Official studies confirm that taking the medication with food does not change the overall amount of drug absorbed, though it may slightly delay the onset of action.

Q: Can Erolin affect sleep quality?

A: Yes, Erolin can potentially affect sleep, as one of the commonly reported side effects in adults and adolescents is insomnia (difficulty falling or staying asleep). If this occurs, it may impact your perceived sleep quality.

Q: What if I take Erolin close to my bedtime?

A: Erolin is taken once daily and official documents do not mandate a specific time of day for administration. If sleep disruption occurs due to insomnia, adjusting the timing of administration might be a consideration, but there is no mandated time of day.

Q: Does Erolin help with pet allergies?

A: Erolin is formally indicated for relieving the symptoms associated with hay fever or other upper respiratory allergies. This general indication typically covers symptoms caused by common environmental allergens, including pet dander.

Q: Are there any visual signs of an Erolin interaction I should look out for?

A: The most concerning visual signs relate to rare, serious adverse events. Regulatory texts describe the need to watch for signs of a severe allergic reaction (like anaphylaxis, which includes swelling of the face or throat) or signs of liver problems (like jaundice or yellowing of the skin/eyes).

Q: Is Erolin commonly used in pediatric allergy treatment?

A: Yes, regulatory documents establish specific dosage instructions for children as young as two to twelve years based on their body weight. This confirms that the drug is an option used by prescribers for treating allergies in the pediatric population.

Q: What should I do if Erolin doesn't seem to control my symptoms?

A: The official product information states that individuals should stop use and seek professional guidance if symptoms do not start to improve or if they get worse while taking Erolin. This is important to ensure proper symptom management.

Q: Is Erolin effective for indoor mold allergies?

A: Erolin is indicated for the temporary relief of symptoms due to hay fever or other upper respiratory allergies. This indication covers symptoms caused by common inhaled allergens, which includes substances found indoors such as mold spores.

Q: Does the time of day I take Erolin matter?

A: The drug is prescribed as a once-daily dose without a mandated time of day. If insomnia (difficulty sleeping) is experienced, considering the timing of the dose may be appropriate, but there is no specific time of day mandated for its administration.

Q: Can Erolin cause dry mouth or nose?

A: Dry mouth is listed in regulatory documents as a common side effect of Erolin. While less frequent, dry nose has also been reported as a possible adverse reaction.

Q: Is it safe to drive after taking Erolin?

A: Although Erolin is a non-sedating antihistamine, it can still cause drowsiness or dizziness in some individuals. Official product warnings state that operating heavy machinery or driving should be avoided until an individual knows how this medicine affects their alertness.

Q: Does Erolin interact with supplements like St. John's Wort?

A: While not specifically listed as a formal contraindication, the use of St. John’s Wort may reduce the effectiveness of Loratadine. This is due to the supplement potentially increasing the rate at which the body metabolizes the drug, and caution is generally noted due to this metabolic effect.

Q: Does Erolin interact with anxiety medications?

A: Official warnings state that Loratadine may potentially increase the sedative effect of other sedative drugs. Since some anxiety medications are classified as Central Nervous System (CNS) depressants, caution is advised when taking them in combination.

Q: What types of allergic reactions does Erolin treat best?

A: Erolin is specifically indicated and studied for the symptoms of allergic rhinitis (sneezing, runny nose, itchy eyes, etc.) and the skin symptoms of chronic urticaria (itchiness and hives/rash). These are the two primary conditions listed in the official labeling.

Q: Is there a generic version of Erolin?

A: The active ingredient in Erolin is Loratadine, which is also the generic name. Because Loratadine is available as a generic drug, lower-cost versions are widely accessible in over-the-counter and prescription forms.

Q: Can Erolin affect hair?

A: The official safety profile includes rare reports of effects on hair. Alopecia (hair loss) is listed as a very rare adverse reaction. Reports of dry hair have also been documented.

How should Erolin be stored and disposed of?

How to Store and Dispose of Erolin?

Regulatory agencies define specific storage and disposal requirements to maintain Erolin's integrity and ensure public safety.

Storage Requirements

Requirement Official Instruction
Temperature Range Store at 20 C to 25 C (68 F to 77 F) (USP Controlled Room Temperature).
Protection Keep in a dry place and protect from excessive moisture; certain liquid forms require protection from light.
Packaging Keep the medication in the original container and ensure the container is tightly closed.
Stability Do not use after the stated expiry date; rapidly-disintegrating tablets should be used immediately upon opening the blister.

Disposal and Safety

All medication must be stored out of the sight and reach of children. Unused or expired Erolin should not be disposed of in wastewater or household trash. The official recommendation is to utilize a drug take-back program or authorized collection site. If such a program is unavailable, follow the home disposal protocol of mixing the drug with an undesirable substance and sealing it before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Erolin found in:

A-Z Index: